Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tepotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 19/20 | 0.98 |
| ▸ | NQO2 | P16083 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tepotinib SCHEMBL29550043 | 1.00 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1295616 | 1.00 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL30259391 | 1.00 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1296895 | 0.99 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL29379106 | 0.99 | MET (1.00) | METNQO2 | |
| Hydrochloric Acid SCHEMBL17823301 | 0.92 | MET (0.84) | METNQO2 | |
| SCHEMBL24713684 | 0.92 | MET (0.87) | METNQO2 | |
| SCHEMBL2462861 | 0.92 | MET (0.85) | METNQO2 | |
| SCHEMBL2530219 | 0.91 | MET (0.84) | METNQO2 | |
| SCHEMBL2514982 | 0.91 | MET (0.84) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4599885-A2 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH (DE) | 2025-08-13 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4551226-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-05-14 | — | — | EP | claimed |
| WO-2025080769-A1 | METHODS OF TREATING CANCER | FOGHORN THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4537108-A1 | ALLELIC IMBALANCE OF CHROMATIN ACCESSIBILITY IN CANCER IDENTIFIES CAUSAL RISK VARIANTS AND THEIR MECHANISMS | Dana-Farber Cancer Institute, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20150148351-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2015-05-28 | — | — | US | claimed |
| US-20150044211-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | claimed |
| EP-2827872-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS | Merck Patent GmbH (DE) | 2015-01-28 | — | — | EP | claimed |
| EP-2373640-B1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-30 | — | — | EP | claimed |
| US-20140200221-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-17 | — | — | US | claimed |
| US-8710058-B2 | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | claimed |
| WO-2013139423-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | WO | claimed |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2373640-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200221-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
| US-20150148351-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.